Developer docs
API playgroundTry for free, no card

Search company profiles

etherna immunotherapies

Full company profile

uuid0000zdr

Namestring
etherna immunotherapies
Legal namestring
eTheRNA immunotherapies NV
Websiteurl
etherna.be
Company typeenum
Private
Founded yearint
2013
Descriptiontext

etherna immunotherapies NV is a Belgium-based, privately held platform biotechnology company founded in 2013 as a spin-off from Vrije Universiteit Brussel (VUB). Headquartered in Niel with discovery operations in Ghent and a commercial presence in Boston, etherna develops proprietary messenger RNA (mRNA) chemistry and lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. The company rebranded from eTheRNA Immunotherapies to etherna in October 2023 as it pivoted from internal immunotherapy development toward a partnership-driven platform model under permanent CEO Bernard Sagaert and Chairman Tony de Fougerolles (former founding CSO of Moderna).

etherna's core technology assets include a proprietary library of more than 2,500 distinct ionizable lipids and six specialized LNP platforms — IV delivery for genetic diseases and gene editing, T-cell delivery for immuno-oncology and autoimmune disease, Liver LNP for repeat-dose hepatic expression, Tolerizing LNPs, the iVAX intramuscular vaccine platform, and an Intratumoral platform. The mRNA platform adds proprietary 5' and 3' UTR optimization, codon optimization algorithms, and CleanCap capping. A 2025 breakthrough is the Bio-Reducible LNP platform, which achieves mRNA expression in over 90% of mouse bone marrow hematopoietic stem and progenitor cells (HSPCs), representing a step-change in extrahepatic delivery. Manufacturing is supported by a cGMP-accredited facility in Niel, certified since 2018, with over 30 years of cumulative RNA manufacturing experience.

The business model is partnership-driven and multi-revenue-stream. etherna licenses its mRNA and LNP platforms to pharmaceutical and biotech partners (technology partnering) and co-develops proprietary therapeutic programs (product partnering), generating upfront payments, research funding, development and commercial milestones, and tiered royalties. Notable agreements include up to USD 950 million in potential milestones from Dropshot Therapeutics (cardiac and renal) and up to €300 million from Almirall (dermatology). A GMP manufacturing services business supplies cGMP RNA batches (minimum ~500mg) with CMC regulatory support to clinical-stage programs, and a webshop sells catalog research-grade mRNAs (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) from 100µg to over 50mg to academic and industrial customers. The company also participates in the WHO/MPP mRNA Technology Transfer Program supporting Afrigen Biologics in developing the first African-owned mRNA COVID-19 vaccine.

Short descriptiontext

etherna is a Belgium-based platform biotech developing proprietary mRNA chemistry and lipid nanoparticle (LNP) delivery technologies, partnering with pharmaceutical and biotech companies to co-develop nucleic acid therapeutics from discovery through GMP manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNiel, Belgium
HQ citystring
Niel
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA therapeutics, lipid nanoparticles, RNA-LNP delivery, nucleic acid medicines, GMP RNA manufacturing
Industry2 codes
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Nucleic Acid Therapeutics / mRNA-LNP Technology Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Technology Licensing and Platform Access
TypeLicensing Royalties
Description

etherna licenses its proprietary mRNA chemistry and LNP delivery platforms to pharmaceutical and biotech partners through technology partnering agreements. Partners gain access to customizable lipid nanoparticles and advanced mRNA chemistry in exchange for upfront payments, technology access fees, and ongoing royalties on commercialized products.

etherna.be
2GMP RNA Manufacturing Services
TypeProfessional Services
Description

etherna provides full-range RNA production services from research grade through GMP for partners at all project stages, including process optimization, QC method development, GMP production, stability studies, and CMC regulatory support. Revenue is generated through service fees for manufacturing batches, with minimum quantities of approximately 500mg in clean room environments.

etherna.be
3Research Grade mRNA Products
TypeOne Time License
Description

Sale of off-the-shelf catalog mRNA products (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) and custom research-grade mRNA synthesis. RNA is available from 100µg to gram scale with short delivery times. Revenue is generated through product sales with pricing based on quantity and customization level.

etherna.be
4Milestone Payments
TypeLicensing Royalties
Description

Through co-development partnerships, etherna receives upfront payments, research funding, and success-based development and commercial milestone payments. Notable agreements include up to USD 950 million potential from Dropshot Therapeutics and up to €300 million from Almirall, contingent on development and commercial success of multiple products.

etherna.be
5Royalties on Commercial Sales
TypeLicensing Royalties
Description

Tiered royalties based on future global sales of products developed under partnership agreements, generating ongoing revenue as partner products reach commercialization. Royalties are structured as a percentage of sales with tiered rates based on sales volumes.

etherna.be
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Off-the-shelf catalog mRNA products available in standard quantities from stock
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Catalog mRNAs available starting from 100µg at standard pricing. Quantities up to 50mg are available from stock and can be delivered within 1-2 weeks. Larger quantities and custom specifications are available upon request. Discounts are available for bulk purchases and long-term collaborations.

etherna.be
2Custom mRNA synthesis tailored to specific research requirements
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Custom RNA synthesis services are priced based on quantity, sequence complexity, purification method (silica or column), NTP modifications, and delivery specifications. Pricing is quote-based through contact with the sales team.

etherna.be
3GMP RNA manufacturing services from process development through production
ModelOtherBilling cadenceMulti-year contract
Notes

GMP manufacturing involves a tiered route from Research Grade through Engineering Run to GMP Batch Production. Minimum batch quantity is approximately 500mg in clean room environments. Services include process optimization, QC method development, stability studies, fill-finish options, and CMC regulatory support. Pricing is project-specific and quote-based.

etherna.be
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

etherna immunotherapies is a clinical-stage biotechnology company that designs and supplies proprietary mRNA chemistries and application-tuned lipid nanoparticle (LNP) delivery platforms for nucleic-acid-based therapeutics. The company licenses and co-develops its RNA-LNP technology with pharmaceutical and biotechnology partners, and operates an integrated offering spanning RNA sequence design, LNP formulation, and GMP manufacturing for clinical supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • At least 5-fold improvement in mRNA expression over clinical benchmark LNPs for vaccine applications in NHP studies
+5 more records
Product overview1 text field

etherna is a platform-driven RNA-LNP technology company offering integrated capabilities across RNA chemistry, LNP formulation, and Process Technology. The product portfolio consists of multiple LNP platforms (IV Delivery for genetic diseases/gene editing, T-cell LNP for immuno-oncology, Liver LNP for hepatic expression, Tolerizing LNP for autoimmune diseases, iVAX for prophylactic vaccines, and Intratumoral LNP for cancer immunotherapy), an mRNA Platform for sequence optimization and RNA production, and RNA products (Catalog RNAs, Research Grade RNA, GMP Grade RNA). Services include Technology Partnering for platform access, Product Partnering for therapeutic co-development, and Platform-Integrated Manufacturing. The company operates from research grade through GMP manufacturing in its Belgian facilities.

Product and service1 record
1IV Delivery LNP Platform (Genetic Diseases & Gene Editing)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Dropshot Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-09
Description

Strategic multi-target collaboration combining etherna's mRNA and LNP platforms with Dropshot's cardiac and renal disease biology expertise. The partnership aims to create multiple novel proprietary RNA-based therapeutics and advance them rapidly from preclinical to clinical stages. etherna receives an upfront payment, research funding, and milestone payments potentially worth up to USD 950 million, plus tiered royalties on commercial sales. Dropshot is co-founded by Kenneth R. Chien (Moderna co-founder) and Marijn E. Dekkers (former CEO of Bayer and Thermo Fisher), and is based near Boston, USA.

etherna.be
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-10
Description

Collaborative research leading to publication in Nature Communications demonstrating therapeutic potential of etherna's intratumoral mRNA-LNP platform. The study showed 85% tumor regression in triple-negative breast cancer models using a Triplet combination of IL-21, IL-7, and 4-1BBL mRNAs. The collaboration leverages VIB-VUB's tumor immunology research alongside etherna's mRNA and LNP technology platforms.

3Universiteit Gent (UGent)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-10
Description

Research collaboration partner alongside VIB-VUB in the preclinical cancer immunotherapy study published in Nature Communications, contributing immunology and oncology expertise to the development of etherna's mRNA-LNP intratumoral immunotherapy platform.

etherna.be
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-21
Description

Research collaboration funded by a €1.7 million Flanders Innovation & Entrepreneurship (VLAIO) grant. The project aims to develop a tolerizing mRNA-LNP platform that restores immune homeostasis for deployment across autoimmune diseases, with a particular focus on multiple sclerosis. Combines etherna's mRNA and LNP technologies with UHasselt's immunology expertise through the Biomedical Research Institute (BIOMED).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-12
Description

Multi-target alliance for developing mRNA-based therapies for severe skin diseases including non-melanoma skin cancer. The collaboration leverages etherna's proprietary mRNA and LNP technology with Almirall's medical dermatology expertise. etherna receives upfront and technology access payments, with potential milestone payments of up to €300 million plus tiered royalties contingent on launch and commercial success of multiple products. Almirall leads clinical development and commercialization. A therapy candidate LAD116 has been nominated and is advancing to IND-enabling studies and Phase I clinical trials.

6Afrigen Biologics
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-03-25
Description

Expert development partner supporting Afrigen in developing the first African-owned mRNA COVID-19 vaccine under the WHO/MPP mRNA Technology Transfer Program. etherna provides proprietary lipid technology, thermostable vaccine platform, and LNP formulation expertise to enable manufacturing that can operate in standard refrigeration conditions suitable for low- and middle-income countries. This collaboration was highlighted during a royal visit by HM King Philippe and HM Queen Mathilde of Belgium.

etherna.be
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

Supporting the development of the first African-owned mRNA COVID-19 vaccine as part of the WHO/MPP mRNA Technology Transfer Program. Univercells' Quantoom Biosciences leads mRNA production technology development (Ntensify midi system), while etherna provides proprietary lipids and formulation expertise. The partnership aims to establish distributed vaccine manufacturing capability in Africa and LMICs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research collaboration with VIB's researchers at Vrije Universiteit Brussel on mRNA-LNP cancer immunotherapy. Joint work published in Nature Communications demonstrating 85% tumor regression in preclinical cancer models using etherna's mRNA-LNP Triplet immunotherapy platform.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Co-leader with WHO of the mRNA Technology Transfer Program. MPP collaborates with technology partners including etherna to facilitate technology transfer and manufacturing capacity building in LMICs for mRNA vaccines.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global mRNA therapeutics leader with deep LNP expertise and integrated mRNA design, manufacturing, and commercialization capabilities. Directly comparable to etherna in mRNA-LNP platform technology, though BioNTech operates at vastly larger scale across a broader therapeutic footprint.

TypeBroad incumbent
Description

The most prominent commercial-stage mRNA company, with proprietary LNP technology and end-to-end capabilities from design through commercial manufacturing. Several etherna leaders (Tony de Fougerolles as founding CSO, Kenneth Chien as co-founder) came from Moderna, making it a natural benchmark for platform strategy and scale.

TypeDirect peer
Description

Germany-based mRNA therapeutics company developing prophylactic vaccines and oncology therapies, with proprietary RNA optimization and GMP manufacturing. Closely comparable to etherna in technology focus (mRNA platform, GMP manufacturing) and European base, though CureVac is publicly listed and larger.

TypeDirect peer
Description

Clinical-stage mRNA medicines company with proprietary LUNAR LNP delivery platform and STARR mRNA technology. Directly comparable to etherna in offering a platform-based mRNA-LNP solution with multiple partnered programs, including vaccines and rare disease therapeutics.

TypeDirect peer
Description

Private Canadian company specializing in lipid nanoparticle delivery systems for mRNA therapeutics, notably the LNP technology used in Comirnaty (Pfizer-BioNTech COVID-19 vaccine). The closest pure-play LNP delivery peer to etherna, competing for pharma partnerships across mRNA programs.

TypeDirect peer
Description

Lipid nanoparticle delivery technology company focused on nucleic acid therapeutics, with a library of ionizable and neutral lipids comparable to etherna's 2,500+ lipid library. Competes directly for pharma LNP licensing and co-development partnerships.

7Translate Bio (Sanofi)
TypeBroad incumbent
Description

mRNA therapeutics company acquired by Sanofi in 2021, focused on vaccines and protein replacement. Directly comparable in mRNA platform focus, though now operating as part of Sanofi's broader portfolio rather than as a standalone platform partner.

TypeEmerging player
Description

Clinical-stage synthetic biology company developing self-replicating mRNA therapeutics for oncology and other diseases. Comparable to etherna as an emerging platform-based mRNA company, with a more focused product portfolio but similar partnering-driven business model.

TypeEmerging player
Description

CDMO providing plasmid DNA, mRNA, and recombinant proteins for therapeutic developers. Comparable to etherna's GMP RNA manufacturing services business, with broader biologics manufacturing capabilities; now part of Danaher's Cytiva life sciences platform.

TypeEmerging player
Description

Belgian mRNA CDMO and technology developer partnering with etherna on the WHO mRNA Technology Transfer Program. Comparable as a mid-stage mRNA manufacturing and technology platform player, with focused mid-scale production equipment rather than full therapeutic pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

etherna immunotherapies

Nucleic Acid Therapeutics / mRNA-LNP Technology Platformetherna.be

etherna is a Belgium-based platform biotech developing proprietary mRNA chemistry and lipid nanoparticle (LNP) delivery technologies, partnering with pharmaceutical and biotech companies to co-develop nucleic acid therapeutics from discovery through GMP manufacturing.

What etherna immunotherapies does

etherna immunotherapies NV is a Belgium-based, privately held platform biotechnology company founded in 2013 as a spin-off from Vrije Universiteit Brussel (VUB). Headquartered in Niel with discovery operations in Ghent and a commercial presence in Boston, etherna develops proprietary messenger RNA (mRNA) chemistry and lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. The company rebranded from eTheRNA Immunotherapies to etherna in October 2023 as it pivoted from internal immunotherapy development toward a partnership-driven platform model under permanent CEO Bernard Sagaert and Chairman Tony de Fougerolles (former founding CSO of Moderna).

etherna's core technology assets include a proprietary library of more than 2,500 distinct ionizable lipids and six specialized LNP platforms — IV delivery for genetic diseases and gene editing, T-cell delivery for immuno-oncology and autoimmune disease, Liver LNP for repeat-dose hepatic expression, Tolerizing LNPs, the iVAX intramuscular vaccine platform, and an Intratumoral platform. The mRNA platform adds proprietary 5' and 3' UTR optimization, codon optimization algorithms, and CleanCap capping. A 2025 breakthrough is the Bio-Reducible LNP platform, which achieves mRNA expression in over 90% of mouse bone marrow hematopoietic stem and progenitor cells (HSPCs), representing a step-change in extrahepatic delivery. Manufacturing is supported by a cGMP-accredited facility in Niel, certified since 2018, with over 30 years of cumulative RNA manufacturing experience.

The business model is partnership-driven and multi-revenue-stream. etherna licenses its mRNA and LNP platforms to pharmaceutical and biotech partners (technology partnering) and co-develops proprietary therapeutic programs (product partnering), generating upfront payments, research funding, development and commercial milestones, and tiered royalties. Notable agreements include up to USD 950 million in potential milestones from Dropshot Therapeutics (cardiac and renal) and up to €300 million from Almirall (dermatology). A GMP manufacturing services business supplies cGMP RNA batches (minimum ~500mg) with CMC regulatory support to clinical-stage programs, and a webshop sells catalog research-grade mRNAs (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) from 100µg to over 50mg to academic and industrial customers. The company also participates in the WHO/MPP mRNA Technology Transfer Program supporting Afrigen Biologics in developing the first African-owned mRNA COVID-19 vaccine.

etherna immunotherapies firmographics

Firmographics
Name
etherna immunotherapies
Legal name
eTheRNA immunotherapies NV
Website
https://etherna.be
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
etherna is a Belgium-based platform biotech developing proprietary mRNA chemistry and lipid nanoparticle (LNP) delivery technologies, partnering with pharmaceutical and biotech companies to co-develop nucleic acid therapeutics from discovery through GMP manufacturing.
Ownership category
akta.pro rank

etherna immunotherapies industry classification

Industry
Product category
Nucleic Acid Therapeutics / mRNA-LNP Technology Platform
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • MRNA therapeutics
  • Lipid nanoparticles
  • RNA-LNP delivery
  • Nucleic acid medicines
  • GMP RNA manufacturing

Where etherna immunotherapies is headquartered

Location

Headquarters

HQ city
Niel
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

etherna immunotherapies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing and Platform Access: etherna licenses its proprietary mRNA chemistry and LNP delivery platforms to pharmaceutical and biotech partners through technology partnering agreements. Partners gain access to customizable lipid nanoparticles and advanced mRNA chemistry in exchange for upfront payments, technology access fees, and ongoing royalties on commercialized products.
  2. GMP RNA Manufacturing Services: etherna provides full-range RNA production services from research grade through GMP for partners at all project stages, including process optimization, QC method development, GMP production, stability studies, and CMC regulatory support. Revenue is generated through service fees for manufacturing batches, with minimum quantities of approximately 500mg in clean room environments.
  3. Research Grade mRNA Products: Sale of off-the-shelf catalog mRNA products (eGFP, FLuc, HA, hEPO, Ova, LacZ, mCherry) and custom research-grade mRNA synthesis. RNA is available from 100µg to gram scale with short delivery times. Revenue is generated through product sales with pricing based on quantity and customization level.
  4. Milestone Payments: Through co-development partnerships, etherna receives upfront payments, research funding, and success-based development and commercial milestone payments. Notable agreements include up to USD 950 million potential from Dropshot Therapeutics and up to €300 million from Almirall, contingent on development and commercial success of multiple products.
  5. Royalties on Commercial Sales: Tiered royalties based on future global sales of products developed under partnership agreements, generating ongoing revenue as partner products reach commercialization. Royalties are structured as a percentage of sales with tiered rates based on sales volumes.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOff-the-shelf catalog mRNA products available in standard quantities from stock
Unit PricingPay-as-you-goCustom mRNA synthesis tailored to specific research requirements
OtherMulti-year contractGMP RNA manufacturing services from process development through production

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

etherna immunotherapies product offering

Product offering

Core offering

etherna immunotherapies is a clinical-stage biotechnology company that designs and supplies proprietary mRNA chemistries and application-tuned lipid nanoparticle (LNP) delivery platforms for nucleic-acid-based therapeutics. The company licenses and co-develops its RNA-LNP technology with pharmaceutical and biotechnology partners, and operates an integrated offering spanning RNA sequence design, LNP formulation, and GMP manufacturing for clinical supply.

Product overview

etherna is a platform-driven RNA-LNP technology company offering integrated capabilities across RNA chemistry, LNP formulation, and Process Technology. The product portfolio consists of multiple LNP platforms (IV Delivery for genetic diseases/gene editing, T-cell LNP for immuno-oncology, Liver LNP for hepatic expression, Tolerizing LNP for autoimmune diseases, iVAX for prophylactic vaccines, and Intratumoral LNP for cancer immunotherapy), an mRNA Platform for sequence optimization and RNA production, and RNA products (Catalog RNAs, Research Grade RNA, GMP Grade RNA). Services include Technology Partnering for platform access, Product Partnering for therapeutic co-development, and Platform-Integrated Manufacturing. The company operates from research grade through GMP manufacturing in its Belgian facilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • IV Delivery LNP Platform (Genetic Diseases & Gene Editing)

Quantifiable outcome

  • At least 5-fold improvement in mRNA expression over clinical benchmark LNPs for vaccine applications in NHP studies
  • +5 more outcomes

Companies that use etherna immunotherapies

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

etherna immunotherapies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

etherna immunotherapies partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and flagship.

  • Dropshot TherapeuticscoreStrategic or Co-development Partner · 9 January 2025Strategic multi-target collaboration combining etherna's mRNA and LNP platforms with Dropshot's cardiac and renal disease biology expertise. The partnership aims to create multiple novel proprietary RNA-based therapeutics and advance them rapidly from preclinical to clinical stages. etherna receives an upfront payment, research funding, and milestone payments potentially worth up to USD 950 million, plus tiered royalties on commercial sales. Dropshot is co-founded by Kenneth R. Chien (Moderna co-founder) and Marijn E. Dekkers (former CEO of Bayer and Thermo Fisher), and is based near Boston, USA.
  • VIB-VUB (Vlaams Instituut voor Biotechnology and Vrije Universiteit Brussel)coreStrategic or Co-development Partner · 10 December 2024Collaborative research leading to publication in Nature Communications demonstrating therapeutic potential of etherna's intratumoral mRNA-LNP platform. The study showed 85% tumor regression in triple-negative breast cancer models using a Triplet combination of IL-21, IL-7, and 4-1BBL mRNAs. The collaboration leverages VIB-VUB's tumor immunology research alongside etherna's mRNA and LNP technology platforms.
  • Universiteit Gent (UGent)coreStrategic or Co-development Partner · 10 December 2024Research collaboration partner alongside VIB-VUB in the preclinical cancer immunotherapy study published in Nature Communications, contributing immunology and oncology expertise to the development of etherna's mRNA-LNP intratumoral immunotherapy platform.
  • Hasselt UniversitycoreStrategic or Co-development Partner · 21 May 2024Research collaboration funded by a €1.7 million Flanders Innovation & Entrepreneurship (VLAIO) grant. The project aims to develop a tolerizing mRNA-LNP platform that restores immune homeostasis for deployment across autoimmune diseases, with a particular focus on multiple sclerosis. Combines etherna's mRNA and LNP technologies with UHasselt's immunology expertise through the Biomedical Research Institute (BIOMED).
  • AlmirallcoreStrategic or Co-development Partner · 12 December 2023Multi-target alliance for developing mRNA-based therapies for severe skin diseases including non-melanoma skin cancer. The collaboration leverages etherna's proprietary mRNA and LNP technology with Almirall's medical dermatology expertise. etherna receives upfront and technology access payments, with potential milestone payments of up to €300 million plus tiered royalties contingent on launch and commercial success of multiple products. Almirall leads clinical development and commercialization. A therapy candidate LAD116 has been nominated and is advancing to IND-enabling studies and Phase I clinical trials.
  • Afrigen BiologicsflagshipStrategic or Co-development Partner · 25 March 2023Expert development partner supporting Afrigen in developing the first African-owned mRNA COVID-19 vaccine under the WHO/MPP mRNA Technology Transfer Program. etherna provides proprietary lipid technology, thermostable vaccine platform, and LNP formulation expertise to enable manufacturing that can operate in standard refrigeration conditions suitable for low- and middle-income countries. This collaboration was highlighted during a royal visit by HM King Philippe and HM Queen Mathilde of Belgium.
  • Univercells / Quantoom BiosciencesflagshipStrategic or Co-development Partner · 1 June 2021Supporting the development of the first African-owned mRNA COVID-19 vaccine as part of the WHO/MPP mRNA Technology Transfer Program. Univercells' Quantoom Biosciences leads mRNA production technology development (Ntensify midi system), while etherna provides proprietary lipids and formulation expertise. The partnership aims to establish distributed vaccine manufacturing capability in Africa and LMICs.
  • VIB (Vlaams Instituut voor Biotechnology)coreStrategic or Co-development PartnerLong-standing research collaboration with VIB's researchers at Vrije Universiteit Brussel on mRNA-LNP cancer immunotherapy. Joint work published in Nature Communications demonstrating 85% tumor regression in preclinical cancer models using etherna's mRNA-LNP Triplet immunotherapy platform.
  • Medicines Patent Pool (MPP)flagshipStrategic or Co-development PartnerCo-leader with WHO of the mRNA Technology Transfer Program. MPP collaborates with technology partners including etherna to facilitate technology transfer and manufacturing capacity building in LMICs for mRNA vaccines.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

etherna immunotherapies competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: Global mRNA therapeutics leader with deep LNP expertise and integrated mRNA design, manufacturing, and commercialization capabilities. Directly comparable to etherna in mRNA-LNP platform technology, though BioNTech operates at vastly larger scale across a broader therapeutic footprint.
  • Moderna: The most prominent commercial-stage mRNA company, with proprietary LNP technology and end-to-end capabilities from design through commercial manufacturing. Several etherna leaders (Tony de Fougerolles as founding CSO, Kenneth Chien as co-founder) came from Moderna, making it a natural benchmark for platform strategy and scale.
  • Translate Bio (Sanofi): mRNA therapeutics company acquired by Sanofi in 2021, focused on vaccines and protein replacement. Directly comparable in mRNA platform focus, though now operating as part of Sanofi's broader portfolio rather than as a standalone platform partner.

Direct peers

  • CureVac: Germany-based mRNA therapeutics company developing prophylactic vaccines and oncology therapies, with proprietary RNA optimization and GMP manufacturing. Closely comparable to etherna in technology focus (mRNA platform, GMP manufacturing) and European base, though CureVac is publicly listed and larger.
  • Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LUNAR LNP delivery platform and STARR mRNA technology. Directly comparable to etherna in offering a platform-based mRNA-LNP solution with multiple partnered programs, including vaccines and rare disease therapeutics.
  • Acuitas Therapeutics: Private Canadian company specializing in lipid nanoparticle delivery systems for mRNA therapeutics, notably the LNP technology used in Comirnaty (Pfizer-BioNTech COVID-19 vaccine). The closest pure-play LNP delivery peer to etherna, competing for pharma partnerships across mRNA programs.
  • Genevant Sciences: Lipid nanoparticle delivery technology company focused on nucleic acid therapeutics, with a library of ionizable and neutral lipids comparable to etherna's 2,500+ lipid library. Competes directly for pharma LNP licensing and co-development partnerships.

Emerging players

  • Strand Therapeutics: Clinical-stage synthetic biology company developing self-replicating mRNA therapeutics for oncology and other diseases. Comparable to etherna as an emerging platform-based mRNA company, with a more focused product portfolio but similar partnering-driven business model.
  • Aldevron (Danaher): CDMO providing plasmid DNA, mRNA, and recombinant proteins for therapeutic developers. Comparable to etherna's GMP RNA manufacturing services business, with broader biologics manufacturing capabilities; now part of Danaher's Cytiva life sciences platform.
  • Quantoom Biosciences (Univercells): Belgian mRNA CDMO and technology developer partnering with etherna on the WHO mRNA Technology Transfer Program. Comparable as a mid-stage mRNA manufacturing and technology platform player, with focused mid-scale production equipment rather than full therapeutic pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

etherna immunotherapies social profiles

Digital presence

etherna immunotherapies compliance and trust

Trust signal

Compliance1 record

etherna immunotherapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

etherna immunotherapies leadership team

Management profile

Number of profiles

Profiles14 records

etherna immunotherapies funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

etherna immunotherapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about etherna immunotherapies

What does etherna immunotherapies do?

etherna immunotherapies is a clinical-stage biotechnology company that designs and supplies proprietary mRNA chemistries and application-tuned lipid nanoparticle (LNP) delivery platforms for nucleic-acid-based therapeutics. The company licenses and co-develops its RNA-LNP technology with pharmaceutical and biotechnology partners, and operates an integrated offering spanning RNA sequence design, LNP formulation, and GMP manufacturing for clinical supply.

Is etherna immunotherapies a public or private company?

etherna immunotherapies is a private company. It is classified as venture growth investor backed and is currently operating.

When was etherna immunotherapies founded?

etherna immunotherapies was founded in 2013. It employs 51 to 100 people.

Where is etherna immunotherapies based?

etherna immunotherapies is headquartered in Niel, Belgium, in the Europe region.

How does etherna immunotherapies make money?

Five revenue lines are on record. Technology Licensing and Platform Access are the primary driver. The others are GMP RNA Manufacturing Services, research Grade mRNA Products, milestone Payments and royalties on Commercial Sales.

Who are etherna immunotherapies's main competitors?

Broad incumbents on record are BioNTech, Moderna and Translate Bio (Sanofi). Direct peers are CureVac, Arcturus Therapeutics, Acuitas Therapeutics and Genevant Sciences. Emerging players are Strand Therapeutics, Aldevron (Danaher) and Quantoom Biosciences (Univercells).

Does etherna immunotherapies have an API?

No public API is recorded for etherna immunotherapies.

What industry is etherna immunotherapies in?

etherna immunotherapies's product category is Nucleic Acid Therapeutics / mRNA-LNP Technology Platform. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogValerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the ClinicValerio Therapeutics completed its acquisition of Etherna Immunotherapies, settling share consideration after cash closing in August. The deal, valued at €30 million, combines Valerio's antibody libraries with Etherna's mRNA and LNP technologies to build an integrated RNA platform. Valerio aims to advance at least one proprietary program into first-in-human studies within 18–24 months.YahooValerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the ClinicValerio Therapeutics completed its acquisition of Etherna Immunotherapies, settling share consideration after cash payment in August. The deal, valued at €30 million, is financed by €40.25 million in new shares. Valerio aims to advance at least one proprietary program to first-in-human studies within 18-24 months.Business Wire BlogValerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From NewValerio Therapeutics signed a definitive agreement to acquire 100% of Etherna Immunotherapies for €30 million enterprise value, plus a €40.25 million PIPE financing. The deal will be settled with cash and shares, subject to shareholder approval expected in October 2026.MorningstarValerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From NewValerio Therapeutics signed definitive agreements to acquire Etherna Immunotherapies for €30 million, plus a €40.25 million PIPE financing. The deal will be settled with cash and shares, and shareholder approval is secured from over 70% of voting rights. The combined company aims to develop RNA medicines targeting tissues beyond the liver.Ethernaetherna Acquisition by Valerio: A New Milestone AchievedValerio Therapeutics signed definitive agreements to acquire Etherna Immunotherapies for €30 million, plus a €40.25 million PIPE financing. The deal combines Etherna's RNA and LNP platforms with Valerio's cell-targeting technologies to target tissues beyond the liver. Shareholder approval is expected on October 6, 2026.ValeriotxValerio Therapeutics announces signing of definitive agreements for the acquisition of Etherna Immunotherapies, building a leading platform in targeted RNA, and €40.25 million PIPE financing from newValerio Therapeutics signed definitive agreements to acquire Etherna Immunotherapies for €30 million and raised €40.25 million in PIPE financing. The deal will fund the cash portion and support development of RNA therapeutics targeting tissues beyond the liver. Shareholder approval is expected on October 6, 2026.Pulse 2.0Valerio Targets August 21 Signing For €30 Million Etherna Acquisition After Receiving FDI ClearanceValerio Therapeutics has received foreign direct investment clearance and is targeting August 21 to sign definitive agreements for its €30 million acquisition of Etherna Immunotherapies. This regulatory approval removes a key condition, allowing the companies to finalize contractual terms for the transaction which aims to expand Valerio's RNA therapeutics platform. The deal remains subject to further closing conditions and execution risk before ownership transfers.YahooValerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated AcquisitionValerio Therapeutics is finalizing transaction documentation for its planned acquisition of 100% of Etherna Immunotherapies, having secured the necessary foreign direct investment clearance. The companies aim to sign the definitive agreements by August 21, 2026, following an initial binding offer based on an enterprise value of EUR 30 million submitted in July 2026.MorningstarValerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated AcquisitionValerio Therapeutics submitted a binding offer to acquire Etherna Immunotherapies for EUR 30 million on July 1, 2026. The parties have made progress, including receiving foreign direct investment clearance, and aim to sign the definitive agreements by August 21, 2026.AInvestValerio Therapeutics announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicinesValerio Therapeutics has announced a binding offer to acquire Etherna Immunotherapies, combining its precision-guided therapeutics expertise with Etherna's mRNA and lipid nanoparticle delivery platforms to create a global leader in targeted RNA medicines. Etherna, based in Niel, Belgium, brings proprietary LNP formulations and an existing strategic partnership with Dropshot Therapeutics potentially worth USD 950 million. The acquisition, aligned with Valerio's strategic roadmap under new CEO Gilles Besin, aims to accelerate development of next-generation nucleic acid-based treatments in oncology, infectious diseases, and autoimmune disorders.